Evidence map›Paper›PMID 34201393›Full record

ReviewInternational journal of molecular sciences2021

Eph Receptors and Ephrins in Retinal Diseases.

Radoslaw Kaczmarek, Pawel Gajdzis, Malgorzata Gajdzis

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Ephrin B1 Regulates Inflammatory Pathways in Retinal Müller Cells.Journal of diabetes and clinical research · 2024
    Article
  8. Review
  9. Effects ofMolecules (Basel, Switzerland) · 2022
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Radoslaw KaczmarekDepartment of Ophthalmology, Wroclaw Medical University, 50-556 Wroclaw, Poland.ORCID 0000-0001-9920-4406
Pawel GajdzisDepartment of Pathomorphology and Oncological Cytology, Wroclaw Medical University, 50-556 Wroclaw, Poland.ORCID 0000-0003-3967-7169
Malgorzata GajdzisDepartment of Ophthalmology, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Wroclaw Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinal diseases are the leading cause of irreversible blindness. They affect people of all ages, from newborns in retinopathy of prematurity, through age-independent diabetic retinopathy and complications of retinal detachment, to age-related macular degeneration (AMD), which occurs mainly in the elderly. Generally speaking, the causes of all problems are disturbances in blood supply, hypoxia, the formation of abnormal blood vessels, and fibrosis. Although the detailed mechanisms underlying them are varied, the common point is the involvement of Eph receptors and ephrins in their pathogenesis. In our study, we briefly discussed the pathophysiology of the most common retinal diseases (diabetic retinopathy, retinopathy of prematurity, proliferative vitreoretinopathy, and choroidal neovascularization) and collected available research results on the role of Eph and ephrins. We also discussed the safety aspect of the use of drugs acting on Eph and ephrin for ophthalmic indications.

Indexed as

AnimalsEphrinsHumansReceptors, Eph FamilyRetinal DiseasesRetinal NeovascularizationEphrinsReceptors, Eph Familyage-related macular degenerationchoroidal neovascularizationdiabetic retinopathyEphEph receptorsephrinproliferative vitreoretinopathyretinaretinopathy of prematurity

Identifiers

PMID34201393
PMCPMC8227845
OpenAlexW3168530307

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.